How to access Elaprase from Qatar — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Qatari patient with Hunter syndrome (mucopolysaccharidosis type II, MPS II) — an X-linked inherited lysosomal storage disorder — may receive a prescription for Elaprase (idursulfase) from their treating metabolic specialist or paediatric geneticist as enzyme-replacement therapy. Elaprase is FDA-approved in the United States for long-term treatment of Hunter syndrome. In Qatar, Elaprase may not always be routinely stocked locally, which is why your specialist may be coordinating a named-patient import pathway on your behalf for ongoing weekly infusion supply.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Elaprase is an intravenous enzyme-replacement therapy (recombinant human iduronate-2-sulfatase) administered as a weekly infusion. Eligibility requires biochemical and/or genetic confirmation of Hunter syndrome. The manufacturer is Takeda (via Shire). Dosing is typically 0.5 mg/kg IV once weekly. The product requires refrigerated storage (2–8 degrees C) and reconstitution before infusion. Monitoring includes urinary GAG levels, pulmonary function, cardiac parameters, joint/skeletal status, infusion-reaction surveillance, and antibody response. Your specialist will confirm Hunter syndrome diagnosis and coordinate the infusion plan.
Is Elaprase legally importable into Qatar?
Yes — through the Qatar Ministry of Public Health (MOPH) named-patient import framework, administered via the administering hospital's importing pharmacy and the MOPH Pharmacy and Drug Control Department. Qatar has a mature named-patient mechanism that supports cross-border access to rare-disease enzyme-replacement therapies.
The framework rests on four anchors: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Because Elaprase is cold-chain, chain-of-custody documentation includes continuous temperature logging.
How the pathway works, step by step
- Consultation with your treating specialist. The decision to prescribe Elaprase is clinical, based on Hunter syndrome confirmation and organ-system status. Your specialist documents the rationale.
- Infusion-facility identification. A Qatari tertiary hospital or infusion centre equipped for weekly enzyme-replacement infusions accepts the case.
- MOPH named-patient application. Your physician or the hospital's importing pharmacy files an application with MOPH including clinical rationale, patient identifier, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Cold-chain shipment. Elaprase travels with validated cold-chain packaging and continuous temperature logging end to end.
- Arrival and infusion. The infusion centre receives the product and administers under your specialist's care. Reserve Meds coordinates the next cycle ahead of depletion, reflecting the weekly cadence.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming Hunter syndrome diagnosis and Elaprase as the indicated therapy
- Verification of their Qatar medical licence (MOPH / QCHP)
- A current prescription naming the product, dose (mg/kg), and weekly infusion schedule
- Patient identifier (anonymised reference preferred)
- The identified infusion facility and its cold-chain handling capability
Reserve Meds provides a physician documentation kit bundling the templates MOPH reviewers expect to see for named-patient import of cold-chain rare-disease enzyme-replacement therapies.
Costs and timing
Elaprase's US cash-pay reference price is weight-dependent. A typical paediatric annual cost sits in an indicative 2026 range of roughly USD 400,000–650,000 for ongoing weekly infusions (adult costs scale with weight). Logistics, MOPH documentation handling, cold-chain shipment, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first shipment arrival after cohort intake opens is approximately 14–28 days from the moment a complete MOPH application is submitted. Subsequent cycles are scheduled to match the weekly infusion calendar.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Elaprase specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for MOPH review.
- Logistics. Cold-chain shipment and chain-of-custody coordination with temperature logging.
- Concierge case lead. A named point of contact for your family and your physician throughout the weekly-infusion cycle.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating metabolic specialist and the infusion facility. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in Qatar? Yes, when executed through the MOPH named-patient framework with appropriate documentation. The pathway has been used across rare disease for many years. See our trust and compliance page.
Why weekly infusions? Elaprase's pharmacokinetics require weekly dosing to maintain enzyme activity. Your specialist will discuss home-infusion versus hospital-infusion options.
What if the cold chain breaks? Our protocol logs temperature continuously; any excursion is assessed against manufacturer stability data. If the product is compromised, we re-source at our cost per service terms.
Will private insurance or MOH coverage apply? Cash-pay is the default. Some Qatari private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Elaprase coordination in Qatar.
Add me to the Elaprase waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.